Johnson & Johnson (JNJ.US) taquitumab in China to be included in priority review for inhibiting tumor formation and growth

The Zhitong Finance App learned that on September 24, the CDE website showed that Johnson & Johnson (JNJ.US)'s taquitumab (Chinese product name: tolique) will be included in the priority review to treat adult patients with recurrent or refractory multiple myeloma (R/R MM) who have previously received at least first-line treatment (including an anti-CD38 monoclonal antibody and lenalidomide).

Taquitumab is a T-cell-directed bispecific antibody that binds to CD3 receptors expressed on the surface of T cells and GPRC5D expressed on the surface of multiple myeloma cells. Clinical studies have shown that taquitumab inhibits tumor formation and growth by redirecting T cells to induce killing multiple myeloma cells with GPRC5D expression.

The drug was approved for marketing in the US and the European Union in 2023, and then domestically in 2025. The previously approved indication is monotherapy for adult R/R MM patients who have previously received at least third-line treatment (including a proteasome inhibitor, an immunomodulator, and an anti-CD38 antibody).